Gilead's Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study
Feb 19, 2013 - Gilead Sciences today announced topline results from the Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus infection who failed prior treatment.
Join the discussion below, or Read more at Drugs.com.
#1 Feb 19, 2013
Thank God, thank God and good doctors
Add your comments below
|Are depressed kids bully magnets? (Feb '12)||2 hr||gmail sign in||40|
|CDC forced to reveal documents proving Thimeros...||3 hr||friend||1|
|Pregnancy Symptoms - 12 Very Early Symptoms of ... (Jun '07)||4 hr||Hayla||6,823|
|Why US smoking rates are declining faster than ...||5 hr||Pete||1|
|Cardiovascular Health||9 hr||uach||1|
|Smoking may increase kidney disease risk in Afr...||9 hr||Drilling for the ...||9|
|The autism epidemic is rising steadily in Ameri...||12 hr||friend||12|
Find what you want!
Search Health Forum Now
Copyright © 2016 Topix LLC